Indications for: NOVOLIN 70/30
Adults and Children:
Individualize. SC inj only. Rotate inj sites. Onset ~30mins, peak 2–12hrs, duration up to 24hrs.
NOVOLIN 70/30 Contraindications:
During episodes of hypoglycemia.
NOVOLIN 70/30 Warnings/Precautions:
Instruct patients on proper administration of insulin, check insulin label before each injection, and management of hypoglycemia. Do not reuse or share pens, needles, or syringes between patients, even if the needle is changed. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. Increased risk of hyperglycemia or hypoglycemia if changes in physical activity, meal patterns, concomitant medications, renal or hepatic function, insulin regimen, administration site, and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Renal or hepatic impairment. Elderly. Pregnancy. Nursing mothers.
NOVOLIN 70/30 Interactions:
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, salicylates, somatostatin analogs (eg, octreotide), sulfonamide antibiotics. Antagonized by atypical antipsychotics, corticosteroids, isoniazid, niacin, danazol, diuretics, glucagon, phenothiazines, sympathomimetics, somatropin, thyroid hormones, oral contraceptives, estrogens, progestogens, protease inhibitors. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt hypoglycemia.
Hypoglycemia, allergic reactions, inj site reactions, lipodystrophy, weight gain, hypokalemia, peripheral edema.
Generic Drug Availability:
Vials (10mL)—1; FlexPen (3mL)—1